A cysteine protease inhibitor rescues mice from a lethal Cryptosporidium parvum infection

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 12, 2013, Pages 6063-6073

  Ndao, Momar ^a   Nath Chowdhury, Milli ^a   Sajid, Mohammed ^b,c   Marcus, Victoria ^d   Mashiyama, Susan T ^g   Sakanari, Judy ^b   Chow, Eric ^b   Mackey, Zachary ^b   Land, Kirkwood M ^b,e   Jacobson, Matthew P ^f,g   Kalyanaraman, Chakrapani ^f,g   McKerrow, James H ^b   Arrowood, Michael J ^h   Caffrey, Conor R ^b  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b University of California at San Francisco   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d MONTREAL GENERAL HOSPITAL   (Canada)

^e UNIVERSITY OF THE PACIFIC   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRYPTOPAIN 1; CRYPTOPAIN 2; CRYPTOPAIN 3; CYSTEINE PROTEINASE; CYSTEINE PROTEINASE INHIBITOR; K 11777; N METHYL PIPERAZINE PHE HOMOPHE VINYLSULFONE PHENYL; PAROMOMYCIN; UNCLASSIFIED DRUG; ANTIPROTOZOAL AGENT; DIPEPTIDE; GAMMA INTERFERON RECEPTOR; INTERFERON RECEPTOR; ISOENZYME; N-PIP-PHENYLALANINE-HOMOPHENYLALANINE-VINYL SULFONE PHENYL; PROTOZOAL PROTEIN; VINYL DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM PARVUM; CYTOTOXICITY TEST; DRUG BLOOD LEVEL; ENTERITIS; ENZYME INHIBITION; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MICROBIAL GROWTH; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OOCYST; PRIORITY JOURNAL; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DEFICIENCY; DRUG ADMINISTRATION; DRUG EFFECTS; ENZYMOLOGY; FEMALE; GENETICS; GROWTH, DEVELOPMENT AND AGING; INTRAPERITONEAL DRUG ADMINISTRATION; KNOCKOUT MOUSE; MALE; METABOLISM; MOLECULAR DOCKING; MORTALITY; ORAL DRUG ADMINISTRATION; PARASITOLOGY; SURVIVAL;

ADMINISTRATION, ORAL; ANIMALS; ANTIPROTOZOAL AGENTS; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM PARVUM; CYSTEINE PROTEASES; CYSTEINE PROTEINASE INHIBITORS; DIPEPTIDES; DRUG ADMINISTRATION SCHEDULE; FEMALE; INJECTIONS, INTRAPERITONEAL; ISOENZYMES; MALE; MICE; MICE, KNOCKOUT; MOLECULAR DOCKING SIMULATION; PROTOZOAN PROTEINS; RECEPTORS, INTERFERON; SURVIVAL ANALYSIS; VINYL COMPOUNDS;

EID: 84887412714     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00734-13     Document Type: Article

References (74)

1. Fayer R, Santin M, Macarisin D. 2010. Cryptosporidium ubiquitum n. sp. in animals and humans. Vet. Parasitol. 172:23-32.
2. O'Donoghue PJ. 1995. Cryptosporidium and cryptosporidiosis in man and animals. Int. J. Parasitol. 25:139-195.
3. Tzipori S, Widmer G. 2008. A hundred-year retrospective on cryptosporidiosis. Trends Parasitol. 24:184-189.
4. Juranek DD. 1995. Cryptosporidiosis: sources of infection and guidelines for prevention. Clin. Infect. Dis. 21(Suppl. 1):S57-S61.
5. Fayer R. 2008. Cryptosporidium and cryptosporidiosis, p 1-42. In Fayer R, Xiao L (ed), General biology. CRC Press, Boca Raton, FL.
6. Smith HV, Rose JB. 1998. Waterborne cryptosporidiosis: current status. Parasitol. Today 14:14-22.
7. Rotz LD, Khan AS, Lillibridge SR, Ostroff SM, Hughes JM. 2002. Public health assessment of potential biological terrorism agents. Emerg. Infect. Dis. 8:225-230.
8. Moran GJ. 2002. Threats in bioterrorism. II. CDC category B and C agents. Emerg. Med. Clin. North Am. 20:311-330.
9. Arrowood MJ, Donaldson K. 1996. Improved purification methods for calf-derived Cryptosporidium parvum oocysts using discontinuous sucrose and cesium chloride gradients. J. Eukaryot. Microbiol. 43:89S.
10. Guerrant RL. 1997. Cryptosporidiosis: an emerging, highly infectious threat. Emerg. Infect. Dis. 3:51-57.
11. DuPont HL, Chappell CL, Sterling CR, Okhuysen PC, Rose JB, Jakubowski W. 1995. The infectivity of Cryptosporidium parvum in healthy volunteers. N. Engl. J. Med. 332:855-859.
12. Janoff EN, Mead PS, Mead JR, Echeverria P, Bodhidatta L, Bhaibulaya M, Sterling CR, Taylor DN. 1990. Endemic Cryptosporidium and Giardia lamblia infections in a Thai orphanage. Am. J. Trop. Med. Hyg. 43: 248-256.
13. Griffiths JK. 1998. Human cryptosporidiosis: epidemiology, transmission, clinical disease, treatment, and diagnosis. Adv. Parasitol. 40:37-85.
14. Mead JR. 2002. Cryptosporidiosis and the challenges of chemotherapy. Drug Resist. Updat. 5:47-57.
15. Hewitt RG, Yiannoutsos CT, Higgs ES, Carey JT, Geiseler PJ, Soave R, Rosenberg R, Vazquez GJ, Wheat LJ, Fass RJ, Antoninievic Z, Walawander AL, Flanigan TP, Bender JF. 2000. Paromomycin: no more effective than placebo for treatment of cryptosporidiosis in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trial Group. Clin. Infect. Dis. 31:1084-1092.
16. Davies AP, Chalmers RM. 2009. Cryptosporidiosis. BMJ 339:b4168.
17. Capparelli EV, Syed SS. 2008. Nitazoxanide treatment of Cryptosporidium parvum in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J. 27:1041.
18. Amadi B, Mwiya M, Musuku J, Watuka A, Sianongo S, Ayoub A, Kelly P. 2002. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet 360: 1375-1380.
19. Zulu I, Kelly P, Njobvu L, Sianongo S, Kaonga K, McDonald V, Farthing M, Pollok R. 2005. Nitazoxanide for persistent diarrhoea in Zambian acquired immune deficiency syndrome patients: a randomizedcontrolled trial. Aliment. Pharmacol. Ther. 21:757-763.
20. Amadi B, Mwiya M, Sianongo S, Payne L, Watuka A, Katubulushi M, Kelly P. 2009. High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial. BMC Infect. Dis. 9:195.
21. McKerrow JH, Sun E, Rosenthal PJ, Bouvier J. 1993. The proteases and pathogenicity of parasitic protozoa. Annu. Rev. Microbiol. 47:821-853.
22. Koussis K, Withers-Martinez C, Yeoh S, Child M, Hackett F, Knuepfer E, Juliano L, Woehlbier U, Bujard H, Blackman MJ. 2009. A multifunctional serine protease primes the malaria parasite for red blood cell invasion. EMBO J. 28:725-735.
23. Teo CF, Zhou XW, Bogyo M, Carruthers VB. 2007. Cysteine protease inhibitors block Toxoplasma gondii microneme secretion and cell invasion. Antimicrob. Agents Chemother. 51:679-688.
24. McKerrow JH, Caffrey C, Kelly B, Loke P, Sajid M. 2006. Proteases in parasitic diseases. Annu. Rev. Pathol. 1:497-536.
25. Rawlings ND, Barrett AJ, Bateman A. 2012. MEROPS: the database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res. 40:D343-D350.
26. Na BK, Kang JM, Cheun HI, Cho SH, Moon SU, Kim TS, Sohn WM. 2009. Cryptopain-1, a cysteine protease of Cryptosporidium parvum, does not require the pro-domain for folding. Parasitology 136:149-157.
27. Clayton C, Adams M, Almeida R, Baltz T, Barrett M, Bastien P, Belli S, Beverley S, Biteau N, Blackwell J, Blaineau C, Boshart M, Bringaud F, Cross G, Cruz A, Degrave W, Donelson J, El-Sayed N, Fu G, Ersfeld K, Gibson W, Gull K, Ivens A, Kelly J, Vanhamme L. 1998. Genetic nomenclature for Trypanosoma and Leishmania. Mol. Biochem. Parasitol. 97:221-224.
28. Caffrey CR, Steverding D. 2009. Kinetoplastid papain-like cysteine peptidases. Mol. Biochem. Parasitol. 167:12-19.
29. Abrahamsen MS, Templeton TJ, Enomoto S, Abrahante JE, Zhu G, Lancto CA, Deng M, Liu C, Widmer G, Tzipori S, Buck GA, Xu P, Bankier AT, Dear PH, Konfortov BA, Spriggs HF, Iyer L, Anantharaman V, Aravind L, Kapur V. 2004. Complete genome sequence of the apicomplexan, Cryptosporidium parvum. Science 304:441-445.
30. Heiges M, Wang H, Robinson E, Aurrecoechea C, Gao X, Kaluskar N, Rhodes P, Wang S, He CZ, Su Y, Miller J, Kraemer E, Kissinger JC. 2006. CryptoDB: a Cryptosporidium bioinformatics resource update. Nucleic Acids Res. 34:D419-D422.
31. Rosenthal PJ, McKerrow JH, Rasnick D, Leech JH. 1989. Plasmodium falciparum: inhibitors of lysosomal cysteine proteinases inhibit a trophozoite proteinase and block parasite development. Mol. Biochem. Parasitol. 35:177-183.
32. Rosenthal PJ, Wollish WS, Palmer JT, Rasnick D. 1991. Antimalarial effects of peptide inhibitors of a Plasmodium falciparum cysteine proteinase. J. Clin. Invest. 88:1467-1472.
33. Engel JC, Doyle PS, Hsieh I, McKerrow JH. 1998. Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection. J. Exp. Med. 188:725-734.
34. Ang KK, Ratnam J, Gut J, Legac J, Hansell E, Mackey ZB, Skrzypczynska KM, Debnath A, Engel JC, Rosenthal PJ, McKerrow JH, Arkin MR, Renslo AR. 2011. Mining a cathepsin inhibitor library for new antiparasitic drug leads. PLoS Negl. Trop. Dis. 5:e1023. doi:10.1371/journal.pntd.0001023.
35. Abdulla MH, Lim KC, Sajid M, McKerrow JH, Caffrey CR. 2007. Schistosomiasis mansoni: novel chemotherapy using a cysteine protease inhibitor. PLoS Med. 4:e14. doi:10.1371/journal.pmed.0040014.
36. Vermeire JJ, Lantz LD, Caffrey CR. 2012. Cure of hookworm infection with a cysteine protease inhibitor. PLoS Negl. Trop. Dis. 6:e1680. doi:10.1371/journal.pntd.0001680.
37. Sajid M, Robertson SA, Brinen LS, McKerrow JH. 2011. Cruzain: the path from target validation to the clinic. Adv. Exp. Med. Biol. 712:100-115.
38. Arrowood MJ, Sterling CR. 1987. Isolation of Cryptosporidium oocysts and sporozoites using discontinuous sucrose and isopycnic Percoll gradients. J. Parasitol. 73:314-319.
39. Von Oettingen J, Nath-Chowdhury M, Ward BJ, Rodloff AC, Arrowood MJ, Ndao M. 2008. High-yield amplification of Cryptosporidium parvum in interferon gamma receptor knockout mice. Parasitology 135: 1151-1156.
40. Roehm NW, Rodgers GH, Hatfield SM, Glasebrook AL. 1991. An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. J. Immunol. Methods 142:257-265.
41. Arrowood MJ, Hurd MR, Mead JR. 1995. A new method for evaluating experimental cryptosporidial parasite loads using immunofluorescent flow cytometry. J. Parasitol. 81:404-409.
42. Caffrey CR, Hansell E, Lucas KD, Brinen LS, Alvarez HA, Cheng J, Gwaltney SL, Roush WR, Stierhof YD, Bogyo M, Steverding D, McKerrow JH. 2001. Active site mapping, biochemical properties and subcellular localization of rhodesain, the major cysteine protease of Trypanosoma brucei rhodesiense. Mol. Biochem. Parasitol. 118:61-73.
43. Greenbaum D, Baruch A, Hayrapetian L, Darula Z, Burlingame A, Medzihradszky KF, Bogyo M. 2002. Chemical approaches for functionally probing the proteome. Mol. Cell. Proteomics 1:60-68.
44. Somoza JR, Zhan H, Bowman KK, Yu L, Mortara KD, Palmer JT, Clark JM, McGrath ME. 2000. Crystal structure of human cathepsin V. Biochemistry 39:12543-12551.
45. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. 2004. UCSF Chimera-a visualization system for exploratory research and analysis. J. Comput. Chem. 25:1605-1612.
46. Pei J, Kim BH, Grishin NV. 2008. PROMALS3D: a tool for multiple protein sequence and structure alignments. Nucleic Acids Res. 36:2295-2300.
47. Mantel N, Haenszel W. 1959. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 22:719-748.
48. Mantel N. 1966. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 50:163-170.
49. Bromme D, Klaus JL, Okamoto K, Rasnick D, Palmer JT. 1996. Peptidyl vinyl sulphones: a new class of potent and selective cysteine protease inhibitors: S2P2 specificity of human cathepsin O2 in comparison with cathepsins S and L. Biochem. J. 315:85-89.
50. Palmer JT, Rasnick D, Klaus JL, Bromme D. 1995. Vinyl sulfones as mechanism-based cysteine protease inhibitors. J. Med. Chem. 38:3193-3196.
51. Engel JC, Doyle PS, Palmer J, Hsieh I, Bainton DF, McKerrow JH. 1998. Cysteine protease inhibitors alter Golgi complex ultrastructure and function in Trypanosoma cruzi. J. Cell Sci. 111:597-606.
52. Schulz F, Gelhaus C, Degel B, Vicik R, Heppner S, Breuning A, Leippe M, Gut J, Rosenthal PJ, Schirmeister T. 2007. Screening of protease inhibitors as antiplasmodial agents. Part I: Aziridines and epoxides. ChemMedChem. 2:1214-1224.
53. Kerr ID, Lee JH, Farady CJ, Marion R, Rickert M, Sajid M, Pandey KC, Caffrey CR, Legac J, Hansell E, McKerrow JH, Craik CS, Rosenthal PJ, Brinen LS. 2009. Vinyl sulfones as antiparasitic agents and a structural basis for drug design. J. Biol. Chem. 284:25697-25703.
54. Rapp C, Kalyanaraman C, Schiffmiller A, Schoenbrun EL, Jacobson MP. 2011. A molecular mechanics approach to modeling protein-ligand interactions: relative binding affinities in congeneric series. J. Chem. Inf. Model. 51:2082-2089.
55. Sajid M, McKerrow JH. 2002. Cysteine proteases of parasitic organisms. Mol. Biochem. Parasitol. 120:1-21.
56. Chalmers RM, Davies AP. 2010. Minireview: clinical cryptosporidiosis. Exp. Parasitol. 124:138-146.
57. Rosenthal PJ. 1998. Proteases of malaria parasites: new targets for chemotherapy. Emerg. Infect. Dis. 4:49-57.
58. Frame MJ, Mottram JC, Coombs GH. 2000. Analysis of the roles of cysteine proteinases of Leishmania mexicana in the host-parasite interaction. Parasitology 121:367-377.
59. Shaw MK, Roos DS, Tilney LG. 2002. Cysteine and serine protease inhibitors block intracellular development and disrupt the secretory pathway of Toxoplasma gondii. Microbes Infect. 4:119-132.
60. Okhuysen PC, Chappell CL, Kettner C, Sterling CR. 1996. Cryptosporidium parvum metalloaminopeptidase inhibitors prevent in vitro excystation. Antimicrob. Agents Chemother. 40:2781-2784.
61. Nesterenko MV, Tilley M, Upton SJ. 1995. A metallo-dependent cysteine proteinase of Cryptosporidium parvum associated with the surface of sporozoites. Microbios 83:77-88.
62. Forney JR, Yang S, Healey MC. 1996. Protease activity associated with excystation of Cryptosporidium parvum oocysts. J. Parasitol. 82:889-892.
63. Pozio E, Morales MA. 2005. The impact of HIV-protease inhibitors on opportunistic parasites. Trends Parasitol. 21:58-63.
64. McKerrow JH, Rosenthal PJ, Swenerton R, Doyle P. 2008. Development of protease inhibitors for protozoan infections. Curr. Opin. Infect. Dis. 21:668-672.
65. Armson A, Meloni BP, Reynoldson JA, Thompson RC. 1999. Assessment of drugs against Cryptosporidium parvum using a simple in vitro screening method. FEMS Microbiol. Lett. 178:227-233.
66. Yang S, Healey MC. 1993. The immunosuppressive effects of dexamethasone administered in drinking water to C57BL/6N mice infected with Cryptosporidium parvum. J. Parasitol. 79:626-630.
67. Mead JR, You X, Pharr JE, Belenkaya Y, Arrowood MJ, Fallon MT, Schinazi RF. 1995. Evaluation of maduramicin and alborixin in a SCID mouse model of chronic cryptosporidiosis. Antimicrob. Agents Chemother. 39:854-858.
68. You X, Mead JR. 1998. Characterization of experimental Cryptosporidium parvum infection in IFN-gamma knockout mice. Parasitology 117:525-531.
69. Griffiths JK, Theodos C, Paris M, Tzipori S. 1998. The gamma interferon gene knockout mouse: a highly sensitive model for evaluation of therapeutic agents against Cryptosporidium parvum. J. Clin. Microbiol. 36: 2503-2508.
70. Rehg JE. 1991. Activity of azithromycin against cryptosporidia in immunosuppressed rats. J. Infect. Dis. 163:1293-1296.
71. McKerrow JH, Engel JC, Caffrey CR. 1999. Cysteine protease inhibitors as chemotherapy for parasitic infections. Bioorg. Med. Chem. 7:639-644.
72. Renslo AR, McKerrow JH. 2006. Drug discovery and development for neglected parasitic diseases. Nat. Chem. Biol. 2:701-710.
73. Xing R, Addington AK, Mason RW. 1998. Quantification of cathepsins B and L in cells. Biochem. J. 332:499-505.
74. Steverding D, Sexton DW, Wang X, Gehrke SS, Wagner GK, Caffrey CR. 2012. Trypanosoma brucei: chemical evidence that cathepsin L is essential for survival and a relevant drug target. Int. J. Parasitol. 42:481-488.